Table 4 Pooled analysis of hormone replacement therapy use before diagnosis and cancer-specific mortality in England, Scotland and Wales.

Cancer site	HRT user		HRT non-user		HRT user v non-user
	Cancer- deaths	Person-years	Cancer- deaths	Person-years	Unadjusted HR (95% CI)	P^b	Adjusted^a HR (95% CI)	P^c
Colorectal	442	10188	10363	156337	0.82 (0.71, 0.93)	0.003	0.86 (0.77, 0.97)	0.013
Oesophagus	136	615	3366	9359	0.81 (0.69, 0.97)	0.019	0.93 (0.78, 1.11)	0.405
Gastric	121	816	2798	11012	0.85 (0.71, 1.02)	0.085	0.91 (0.75, 1.09)	0.307
Liver	82	233	2227	4177	0.81 (0.65, 1.01)	0.06	0.87 (0.69, 1.09)	0.212
Pancreas	302	564	6376	8062	0.82 (0.73, 0.92)	0.001	0.88 (0.73, 1.06)	0.178
Lung	1519	3946	29327	62587	0.90 (0.82, 0.98)	0.015	0.95 (0.88, 1.02)	0.145
Melanoma	83	9409	1051	90680	0.86 (0.69, 1.08)	0.201	0.86 (0.68, 1.08)	0.197
Cervix	30-35	1313	1354	26350	0.64 (0.46, 0.90)	0.011	0.69 (0.49, 0.98)	0.037
Ovary	496	5363	6761	60621	0.85 (0.64, 1.12)	0.249	0.97 (0.85, 1.11)	0.673
Uterus	76	5714	2548	116211	0.77 (0.56, 1.06)	0.111	1.00 (0.74, 1.33)	0.977
Kidney	101	2448	2197	32859	0.75 (0.61, 0.92)	0.006	0.84 (0.68, 1.03)	0.095
Bladder	73	2850	1930	35993	0.71 (0.56, 0.89)	0.003	0.82 (0.65, 1.04)	0.101
Brain	190	507	2867	6420	0.86 (0.74, 1.00)	0.046	0.91 (0.78, 1.06)	0.211
Oral	68	2366	1378	27322	0.73 (0.57, 0.93)	0.011	0.72 (0.55, 0.95)	0.021
Non-Hodgkin lymphoma	122	4356	2612	53874	0.67 (0.55, 0.81)	<0.001	0.79 (0.66, 0.95)	0.014
Myeloma	101	1220	1597	17712	0.83 (0.53, 1.32)	0.438	1.02 (0.72, 1.45)	0.9
Leukaemia	97	2320	2146	30422	0.63 (0.42, 0.95)	0.026	0.77 (0.57, 1.05)	0.1

^aAdjusted model contains age, year, deprivation, Charlson comorbidities (before diagnosis), medication use (before diagnosis: statin, aspirin, metformin, oral contraceptive) and hysterectomy/oophorectomy (before diagnosis).
^bP value from unadjusted Cox regression model.
^cP value from adjusted Cox regression model.

Quick links

Search